Type 2 diabetes tablet promotes weight loss

(Medical Xpress)—A new drug for type 2 diabetes, involving research at Aston University is being launched as a once-daily tablet for adults with the condition.

Bristol-Myers Squibb and AstraZeneca have launched FORXIGATM (dapagliflozin), a drug which acts independently of insulin to improve and lower body weight.

Professor Clifford Bailey, Professor of Clinical Science at Aston University, has led research into dapagliflozin, a new class of treatments called sodium-glucose cotransporter (SGLT2) inhibitors. These reduce the amount of glucose reabsorbed in the kidney so that excess glucose is passed out of the body via the urine each day.

Professor Bailey's study of patients with type 2 diabetes using dapagliflozin, has provided key information about the drug, which was recently approved for the treatment of this condition. Research showed that it lowers the patient's and promotes weight loss, unlike some diabetes medications that are associated with weight gain.

Dapagliflozin is for use in combination with other glucose lowering treatments, including insulin when these, together with diet and exercise, do not provide adequate blood glucose control in patients. Dapagliflozin can also be used as a monotherapy if diet and exercise do not work in patients for whom the blood glucose lowering agent metformin is not tolerated.

Type 2 Diabetesis a characterized by in the context of and relative . It is initially managed by increasing exercise and dietary modification. If blood glucose levels are not adequately lowered by these measures, medications such as metformin or insulin may be needed. In those on insulin, there is typically the requirement to routinely check blood sugar levels.

Professor Clifford Bailey, author of; "Effect of dapagliflozin in patients with type 2 diabetes", published in The Lancet, said; "dapagliflozin works in a different way to existing treatments. It removes excess glucose from the body along with the associated calories. This process occurs independently of insulin action. So dapagliflozin can be used in conjunction with most commonly used to lower blood glucose, and has the added benefit of weight loss."

Dr Chris Walton, Consultant Diabetologist and Chair of the Association of British Clinical diabetologists, said; "Specialists in diabetes will be keen to work with GPs to assess the place of this new medicine in the treatment of their patients with ."

FORXIGA (dapagliflozin) has been granted marketing authorisation by the European Commission and will be marketed by Bristol-Myers Squibb and AstraZeneca from December 2012.

More information: www.thelancet.com/journals/lan… (10)60407-2/abstract

add to favorites email to friend print save as pdf

Related Stories

Dapagliflozin aids glycemic control in type 2 diabetes

Mar 20, 2012

(HealthDay) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according ...

Recommended for you

Nearly 30% of world population is overweight: study

Nov 20, 2014

More than 2.1 billion people globally—or nearly 30 percent of the world's population—are now overweight or obese, with the figure set to rise further by 2030, according to a study published Thursday.

Report: Global obesity costs hits $2 trillion

Nov 20, 2014

The global cost of obesity has risen to $2 trillion annually—nearly as much as smoking or the combined impact of armed violence, war and terrorism, according to a new report released Thursday.

Small cash rewards pay off in weight loss plans

Nov 20, 2014

People who received small cash bonuses for their degree of participation in an Internet weight loss program shed more pounds than those who were not offered bonuses and they kept much of the weight off, according to a new ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.